Company Description
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections.
The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide.
In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications.
NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
| Country | United States |
| IPO Date | Oct 26, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Anil R. Diwan Ph.D. |
Contact Details
Address: 1 Controls Drive Shelton, Connecticut United States | |
| Website | https://www.nanoviricides.com |
Stock Details
| Ticker Symbol | NNVC |
| Exchange | AMEX |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001379006 |
| CUSIP Number | 630087302 |
| ISIN Number | US6300873022 |
| Employer ID | 76-0674577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anil R. Diwan Ph.D. | Executive Chairman, President, Chief Executive Officer & Secretary |
| Meeta R. Vyas B.S., M.B.A., MBA, SB | Chief Financial Officer & Compliance Officer |
| Dr. Randall W. Barton Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Oct 15, 2024 | DEF 14A | Filing |
| Sep 27, 2024 | 10-K | Annual Report |
| Aug 09, 2024 | 8-K | Current Report |
| Aug 09, 2024 | 424B5 | Filing |
| May 15, 2024 | 10-Q | Quarterly Report |
| Apr 05, 2024 | 8-K | Current Report |
| Apr 05, 2024 | 424B5 | Filing |
| Feb 16, 2024 | 8-K | Current Report |